Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine.
Optimizing treatment goals in ulcerative colitis requires recognizing the needs of patients. It is increasingly recognized that adapting treatment strategies aligned with patient needs can improve patient compliance and consequently minimize relapse rates. Tailoring of treatment strategies can improve not only patient quality of life, and decrease the number harmed by adverse events from more potent drugs, but can also save valuable healthcare costs by avoiding high-cost treatment interventions associated with acute ulcerative colitis. This review will consider several elements of mesalazine management from the patient perspective based on a range of clinical and patient-focused evidence. By highlighting patient preferences in disease management it is envisaged that this review will aid physicians to optimize treatment decisions with the different mesalazine preparations available.
Munkholm
Pia
P
Gastrointestinal Unit, Medical Section, Herlev Hospital, University of Copenhagen, DK-2730 Herlev, Denmark. piamun01@heh.regionh.dk
Michetti
Pierre
P
Probert
Chris S
CS
Elkjaer
Margarita
M
Marteau
Philippe
P
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D010349:Patient Compliance; D057240:Patient Preference; D011349:Proctitis / Q000188:drug therapy; D011788:Quality of Life; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine